These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 29540652)
1. Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsadogenic risk of fexofenadine. Ando K; Nakamura Y; Hagiwara-Nagasawa M; Harada H; Miyamoto H; Inamura N; Takagi K; Goto A; Chiba K; Lubna NJ; Izumi-Nakaseko H; Naito AT; Sugiyama A J Toxicol Sci; 2018; 43(3):183-192. PubMed ID: 29540652 [TBL] [Abstract][Full Text] [Related]
2. Electropharmacological effects of amantadine on cardiovascular system assessed with J-Tpeak and Tpeak-Tend analysis in the halothane-anesthetized beagle dogs. Cao X; Nakamura Y; Wada T; Izumi-Nakaseko H; Ando K; Sugiyama A J Toxicol Sci; 2016; 41(3):439-47. PubMed ID: 27193735 [TBL] [Abstract][Full Text] [Related]
3. Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. Cao X; Wada T; Nakamura Y; Matsukura S; Izumi-Nakaseko H; Ando K; Naito AT; Sugiyama A Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):465-470. PubMed ID: 28654209 [TBL] [Abstract][Full Text] [Related]
4. Electropharmacological Characterization of Aciclovir in the Halothane-Anesthetized Dogs: A Proposal of Evaluation Method for Cardiovascular Safety Pharmacology of Anti-virus Drugs. Kondo Y; Hagiwara-Nagasawa M; Kambayashi R; Goto A; Chiba K; Nunoi Y; Izumi-Nakaseko H; Matsumoto A; Sugiyama A Cardiovasc Toxicol; 2020 Aug; 20(4):419-426. PubMed ID: 32193875 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. Terrien MH; Rahm F; Fellrath JM; Spertini F J Allergy Clin Immunol; 1999 Jun; 103(6):1025-30. PubMed ID: 10359881 [TBL] [Abstract][Full Text] [Related]
6. Analysis of electropharmacological and proarrhythmic effects of donepezil using the halothane-anesthetized intact dogs and the conscious chronic atrioventricular block ones. Hagiwara-Nagasawa M; Kambayashi R; Goto A; Nunoi Y; Izumi-Nakaseko H; Chiba K; Wada T; Takei Y; Matsumoto A; Sugiyama A Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):581-589. PubMed ID: 33064166 [TBL] [Abstract][Full Text] [Related]
7. Analysis of proarrhythmic potential of an atypical antipsychotic drug paliperidone in the halothane-anesthetized dogs. Chiba K; Wada T; Nakamura Y; Cao X; Hagiwara-Nagasawa M; Izumi-Nakaseko H; Ando K; Tanaka K; Naito AT; Sugiyama A J Pharmacol Sci; 2017 Aug; 134(4):239-246. PubMed ID: 28844424 [TBL] [Abstract][Full Text] [Related]
8. Cardiohemodynamic and electrophysiological effects of a selective EP4 receptor agonist ONO--AE1--329 in the halothane-anesthetized dogs. Nomura H; Nakamura Y; Cao X; Honda A; Katagi J; Ohara H; Izumi-Nakaseko H; Satoh Y; Ando K; Sugiyama A Eur J Pharmacol; 2015 Aug; 761():217-25. PubMed ID: 26073024 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Russell T; Stoltz M; Weir S Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426 [TBL] [Abstract][Full Text] [Related]
11. A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node--ablated, His bundle-paced dog. Nolan ER; Feng MR; Koup JR; Liu J; Turluck D; Zhang Y; Paulissen JB; Olivier NB; Miller T; Bailie MB J Pharmacol Toxicol Methods; 2006; 53(1):1-10. PubMed ID: 16399550 [TBL] [Abstract][Full Text] [Related]
12. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Purohit A; Duvernelle C; Melac M; Pauli G; Frossard N Ann Allergy Asthma Immunol; 2001 Apr; 86(4):387-92. PubMed ID: 11345280 [TBL] [Abstract][Full Text] [Related]
13. Effects of fexofenadine on the early response to nasal allergen challenge. Allocco FT; Votypka V; deTineo M; Naclerio RM; Baroody FM Ann Allergy Asthma Immunol; 2002 Dec; 89(6):578-84. PubMed ID: 12487223 [TBL] [Abstract][Full Text] [Related]
14. The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia. Scherer CR; Lerche C; Decher N; Dennis AT; Maier P; Ficker E; Busch AE; Wollnik B; Steinmeyer K Br J Pharmacol; 2002 Nov; 137(6):892-900. PubMed ID: 12411421 [TBL] [Abstract][Full Text] [Related]
15. Fexofenadine: new preparation. Terfenadine, without cardiotoxicity. Prescrire Int; 1999 Feb; 8(39):11-3. PubMed ID: 10557567 [TBL] [Abstract][Full Text] [Related]
16. Analysis of Safety Margin of Lithium Carbonate Against Cardiovascular Adverse Events Assessed in the Halothane-Anesthetized Dogs. Goto A; Nakamura Y; Lubna NJ; Chiba K; Hagiwara-Nagasawa M; Izumi-Nakaseko H; Ando K; Naito AT; Sugiyama A Cardiovasc Toxicol; 2018 Dec; 18(6):530-536. PubMed ID: 29845450 [TBL] [Abstract][Full Text] [Related]
17. Electropharmacological effects of a spironolactone derivative, potassium canrenoate, assessed in the halothane-anesthetized canine model. Sugiyama A; Satoh Y; Takahara A; Ando K; Wang K; Honsho S; Nakamura Y; Hashimoto K J Pharmacol Sci; 2004 Dec; 96(4):436-43. PubMed ID: 15599107 [TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. Turncliff RZ; Hoffmaster KA; Kalvass JC; Pollack GM; Brouwer KL J Pharmacol Exp Ther; 2006 Aug; 318(2):881-9. PubMed ID: 16690724 [TBL] [Abstract][Full Text] [Related]
19. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration. Zhao R; Kalvass JC; Yanni SB; Bridges AS; Pollack GM Drug Metab Dispos; 2009 Mar; 37(3):529-35. PubMed ID: 19114463 [TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations. Yamazaki-Hashimoto Y; Nakamura Y; Ohara H; Cao X; Kitahara K; Izumi-Nakaseko H; Ando K; Yamazaki H; Ikeda T; Yamazaki J; Sugiyama A J Toxicol Sci; 2015 Feb; 40(1):33-42. PubMed ID: 25560394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]